# A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis

> **NCT02064816** · PHASE4 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 200 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Rebif®
- **DRUG:** Rebif®

## Key facts

- **NCT ID:** NCT02064816
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-31
- **Primary completion:** 2016-04-30
- **Final completion:** 2016-04-30
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2018-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02064816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02064816, "A Study of Rebif® in Subjects With Relapsing Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02064816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*